Fluorescent nanocarriers targeting VCAM-1 for early detection of senescent endothelial cells.
Fiche publication
Date publication
mars 2021
Journal
Nanomedicine : nanotechnology, biology, and medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GOETZ Jacky, Dr LEFEBVRE Olivier, Pr SCHINI-KERTH Valérie, Dr KLYMCHENKO Andrey, Dr AUGER Cyril
Tous les auteurs :
Belcastro E, Rehman AU, Remila L, Park SH, Gong DS, Anton N, Auger C, Lefebvre O, Goetz JG, Collot M, Klymchenko AS, Vandamme TF, Schini-Kerth VB
Lien Pubmed
Résumé
Endothelial senescence has been identified as an early event in the development of endothelial dysfunction, a hallmark of cardiovascular disease. This study developed theranostic nanocarriers (NC) decorated with VCAM-1 antibodies (NC-VCAM-1) in order to target cell surface VCAM-1, which is overexpressed in senescent endothelial cells (ECs) for diagnostic and therapeutic purposes. Incubation of Ang II-induced premature senescent ECs or replicative senescent ECs with NC-VCAM-1 loaded with lipophilic fluorescent dyes showed higher fluorescence signals than healthy EC, which was dependent on the NC size and VCAM-1 antibodies concentration, and not observed following masking of VCAM-1. NC loaded with omega 3 polyunsaturated fatty acid (NC-EPA:DHA 6:1) were more effective than native EPA:DHA 6:1 to prevent Ang II-induced VCAM-1 and p53 upregulation, and SA-β- galactosidase activity in coronary artery segments. These theranostic NC might be of interest to evaluate the extent and localization of endothelial senescence and to prevent pro-senescent endothelial responses.
Mots clés
Endothelial senescence and dysfunction, Nanocarriers, Omega 3 polyunsaturated fatty acid, VCAM-1
Référence
Nanomedicine. 2021 Mar 10;:102379